<DOC>
	<DOC>NCT00132873</DOC>
	<brief_summary>This is a long-term, open-label, extension of the OMC-SXB-7 trial. Participants from the OMC-SXB-7 open-label trial may be entered without any requirement as to length of participation in that trial. Approximately 70 patients are expected to participate at up to 6 investigative centers located in Canada. The trial will continue for up to 24 months or until marketing approval, whichever occurs sooner.</brief_summary>
	<brief_title>Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy</brief_title>
	<detailed_description>This trial will be conducted as a long-term, open-label, extension of the OMC-SXB-7 trial. Participants from the OMC-SXB-7 open-label trial may be entered without any requirement as to length of participation in that trial. Approximately 70 patients are expected to participate at up to 6 investigative centers located in Canada. The trial will continue for up to 24 months or until marketing approval, whichever occurs sooner.</detailed_description>
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Sodium Oxybate</mesh_term>
	<criteria>Remained on satisfactory treatment with Xyrem® therapy in the OMCSXB7 trial Signed and dated an informed consent</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Narcolepsy</keyword>
	<keyword>Cataplexy</keyword>
</DOC>